Yiftach Roth - Brainsway Chief Scientist
| BWAY Stock | USD 23.04 1.15 4.75% |
Insider
Yiftach Roth is Chief Scientist of Brainsway
| Age | 55 |
| Address | 16 Hartum St, Jerusalem, Israel, 9777516 |
| Phone | 972 2 582 4030 |
| Web | https://www.brainsway.com |
Brainsway Management Efficiency
The company has return on total asset (ROA) of 0.0192 % which means that it generated a profit of $0.0192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1095 %, meaning that it created $0.1095 on every $100 dollars invested by stockholders. Brainsway's management efficiency ratios could be used to measure how well Brainsway manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.03 in 2026. Return On Capital Employed is likely to rise to 0.02 in 2026. At this time, Brainsway's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 2 M in 2026, whereas Other Assets are likely to drop slightly above 122.3 K in 2026.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sunday Hoy | Tactile Systems Technology | N/A | |
| Chi Nguyen | Neuropace | 47 | |
| Trent Basarsky | 908 Devices | 56 | |
| Scott Miller | 908 Devices | N/A | |
| Anthony Dias | Delcath Systems | 57 | |
| Casey Hoyt | Viemed Healthcare | 49 | |
| William MD | Viemed Healthcare | 68 | |
| Robin Wagge | Delcath Systems | N/A | |
| Francine MD | Senseonics Holdings Common | 75 | |
| Janelle Strop | Tactile Systems Technology | N/A | |
| Jesse Selnick | Sight Sciences | N/A | |
| Matt Haller | Rxsight | N/A | |
| Steve Araiza | 908 Devices | N/A | |
| Kevin Muir | Delcath Systems | N/A | |
| Michael CRT | Viemed Healthcare | 49 | |
| MS MBA | Delcath Systems | 63 | |
| Maura Fitzpatrick | 908 Devices | 54 | |
| Martha Morrell | Neuropace | 67 | |
| John Ordway | Sight Sciences | N/A | |
| Andre Marquette | Neuropace | N/A | |
| Robert LLB | Viemed Healthcare | 50 | |
Management Performance
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0192 |
Brainsway Leadership Team
Elected by the shareholders, the Brainsway's board of directors comprises two types of representatives: Brainsway inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brainsway. The board's role is to monitor Brainsway's management team and ensure that shareholders' interests are well served. Brainsway's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brainsway's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Jako, Pres CEO | ||
| Ido Marom, Chief Officer | ||
| Colleen Hanlon, Vice Affairs | ||
| Gilead Moiseyev, Chief Officer | ||
| Moria Ankri, VP RD | ||
| Dor Hagai, Vice Operations | ||
| Pr Zangen, Member CoFounder | ||
| Hillegonda Groen, Vice Sales | ||
| Ross Mitchell, Vice Marketing | ||
| Richard MD, Chief Officer | ||
| Menachem Esq, General VP | ||
| Avner Hagai, Founder ViceChairman | ||
| Christopher Boyer, Vice Marketing | ||
| Hadar Levy, Chief Officer | ||
| Yiftach Roth, Chief Scientist | ||
| Aron Tendler, Chief Officer | ||
| Richard Areglado, VP CFO | ||
| Michael Cohen, Vice Sales | ||
| David MD, CoFounder ViceChairman |
Brainsway Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brainsway a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0192 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 414.78 M | ||||
| Shares Outstanding | 19.59 M | ||||
| Shares Owned By Insiders | 6.17 % | ||||
| Shares Owned By Institutions | 31.67 % | ||||
| Number Of Shares Shorted | 60.38 K | ||||
| Price To Book | 6.44 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Brainsway Stock Analysis
When running Brainsway's price analysis, check to measure Brainsway's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainsway is operating at the current time. Most of Brainsway's value examination focuses on studying past and present price action to predict the probability of Brainsway's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainsway's price. Additionally, you may evaluate how the addition of Brainsway to your portfolios can decrease your overall portfolio volatility.